Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD and Safety of LY01005 vs Zoladex in Prostate Cancer
NCT05140512Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Baituowei in prostate cancer (PCa), sponsored by Luye Pharma Group. Primary endpoints: Plasma concentration of goserelin over time, Maximum Plasma Concentration (Cmax) and 1 more. Started Feb 2021; status: completed.
02
Drugs
Baituowei
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05140512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140512.